Hologic
Marlborough, Massachusetts medical technology company focused on women's health, taken private by Blackstone and TPG in April 2026 after about four decades as a listed company.
Industry: Medical technology | Location: Marlborough, United States | Founded: 1985
About Hologic
Hologic is a medical technology company that develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products, with a particular focus on women's health. Founded in 1985, it is headquartered at 250 Campus Drive in Marlborough, Massachusetts. Its products are used for the early detection, diagnosis and treatment of conditions across breast health, gynecological health, skeletal health and related areas of care. Company profiles describe the business as organised around four main units: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Third-party data providers have estimated annual revenue at roughly USD 4 billion and a workforce of about 7,000 people as of fiscal 2024, although the figures differ from one provider to another and are not company-published numbers. Hologic has pursued growth beyond the United States, including in Europe, the Middle East and Africa. In 2019 it opened a training facility in Belgium as part of its effort to expand in those markets. In October 2025, Blackstone and TPG agreed to acquire Hologic in a take-private transaction. The terms were USD 76 per share in cash, plus a non-tradable contingent value right worth up to USD 3 per share linked to Breast Health revenue in fiscal 2026 and 2027, which together implied an enterprise value of about USD 18.3 billion. The cash price represented a 46 percent premium to Hologic's closing share price in May 2025, the last full trading day before reports of takeover interest emerged. Press reports said the two private equity firms had earlier made an offer valued at about USD 16 billion, which the company turned down. The merger agreement included a 45-day go-shop period during which rival proposals could be solicited. Minority investments in the transaction came from a subsidiary of the Abu Dhabi Investment Authority and an affiliate of Singapore's GIC, giving the buyout a Gulf sovereign investor among its backers. Hologic's stockholders approved the merger in February 2026, and trade press reported in April 2026 that funds managed by Blackstone and TPG had completed the acquisition. The shares ceased trading and were delisted from the Nasdaq. Stephen MacMillan, who served as chairman, president and chief executive officer, announced that he would retire when the transaction closed. The company said that during his tenure of more than 12 years its revenue increased 65 percent and its workforce grew by more than 1,500 people. José Almeida was named chief executive officer on completion of the deal, according to MD+DI.
Leadership
- José (Joe) E. Almeida, Chief Executive Officer
- Brian Montgomery, Chief Financial Officer
- Essex Mitchell, Chief Operating Officer
- Vitor Rocha, Chief Executive Officer, Diagnostic Solutions
- Jyoti Gupta, Chief Executive Officer, Breast and Skeletal Health Solutions
- Brandon Schnittker, Chief Executive Officer, GYN Surgical Solutions
- Paul Mascarenhas, Chief Transformation Officer
- Janice Deskus, Chief Human Resources and Communications Officer